- Home
- BIIB vs PFG Comparison
BIIB vs PFG Comparison
Compare BIIB & PFG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- PFG
- Stock Information
- Founded
- BIIB 1978
- PFG 1879
- Country
- BIIB United States
- PFG United States
- Employees
- BIIB N/A
- PFG N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- PFG Specialty Insurers
- Sector
- BIIB Health Care
- PFG Finance
- Exchange
- BIIB Nasdaq
- PFG Nasdaq
- Market Cap
- BIIB 19.9B
- PFG 17.7B
- IPO Year
- BIIB 1991
- PFG N/A
- Fundamental
- Price
- BIIB $132.03
- PFG $85.15
- Analyst Decision
- BIIB Buy
- PFG Hold
- Analyst Count
- BIIB 27
- PFG 14
- Target Price
- BIIB $220.50
- PFG $85.86
- AVG Volume (30 Days)
- BIIB 1.7M
- PFG 1.3M
- Earning Date
- BIIB 04-23-2025
- PFG 04-24-2025
- Dividend Yield
- BIIB N/A
- PFG 3.44%
- EPS Growth
- BIIB 40.28
- PFG 161.96
- EPS
- BIIB 11.18
- PFG 6.68
- Revenue
- BIIB $9,675,900,000.00
- PFG $16,127,700,000.00
- Revenue This Year
- BIIB N/A
- PFG $2.61
- Revenue Next Year
- BIIB N/A
- PFG $5.22
- P/E Ratio
- BIIB $11.81
- PFG $12.68
- Revenue Growth
- BIIB N/A
- PFG 18.02
- 52 Week Low
- BIIB $128.51
- PFG $72.21
- 52 Week High
- BIIB $238.00
- PFG $91.98
- Technical
- Relative Strength Index (RSI)
- BIIB 33.63
- PFG 52.81
- Support Level
- BIIB $138.65
- PFG $82.18
- Resistance Level
- BIIB $144.07
- PFG $85.87
- Average True Range (ATR)
- BIIB 3.56
- PFG 1.82
- MACD
- BIIB -0.86
- PFG 0.03
- Stochastic Oscillator
- BIIB 2.79
- PFG 70.46
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About PFG Principal Financial Group Inc
Principal Financial Group Inc is a leader in Global investment management offering businesses, individuals and institutional clients a wide range of financial products and services, including retirement, asset management and insurance through diverse family of financial services companies. It operates in four business segments that are Retirement and Income Solutions, Principal Global Investors, Principal International, and United States Insurance Solutions. The company receives maximum revenue in the form of premiums.